Over 7 million Americans are living with Alzheimer’s, which slowly erodes memory, cognitive skills and the ability to perform ...

Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in ...

The approval of new antibody medications for Alzheimer's disease—lecanemab and donanemab—and diagnostic tests in the blood ...

World-leading Alzheimer's disease experts, including UCL scientists, are calling for rapid reform in healthcare systems, ...

A dementia expert at the University of Exeter is part of an international panel to outline thechanges needed to for people to ...

Alzheimer’s, the major cause of dementia, affecting millions all across the globe.However, 2025, brought multiple hopeful ...

Researchers highlight the necessity of integrating healthcare reforms with emerging treatments like lecanemab and donanemab to address Alzheimer’s disease. While these drugs offer potential, they are ...

The Therapeutic Goods Administration has given the go ahead to a game-changing new treatment, marking a major step forward in ...

As breakthrough medications are beginning to slow the progression of Alzheimer’s disease, innovations such as virtual reality ...

Researchers also say medications d onanemab and lecanemab, which are currently not approved for use by the NHS, slow the ...

Dementia is a devastating condition that currently affects more than 50 million people worldwide. New breakthroughs in ...